EMC China Lab

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices

Views :
Update time : 2025-03-01

With the implementation of ISO 10993-1:2018, most devices that have prolonged contact with the human body (>30 days) now require an evaluation of chronic toxicity and carcinogenicity as part of their biological risk assessment. In Table A.1 (iso 10993-1:2018), these biological endpoints are marked with an "E", indicating that they must be evaluated during risk assessment. This evaluation can be conducted using existing data, additional endpoint-specific tests, or a justified rationale explaining why additional data are unnecessary. The inclusion of these biological evaluation endpoints has also drawn regulatory attention, with review feedback requiring further refinement of chronic toxicity and carcinogenicity assessments based on Table A.1.

 

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices(图1)


Chronic Toxicity Test (Project Duration: ~8–14 months)

Chronic toxicity is a systemic toxicity study conducted by repeated or continuous exposure to the test sample throughout a significant portion of the animal's lifespan to observe any adverse effects. Animals should be continuously exposed for 6–12 months. When using rodents (rats, mice) for single-dose group studies, each group should include at least 30 animals (15 per sex). The evaluation of repeated exposure studies is based on body weight, clinical observations, hematology, clinical biochemistry, gross pathology, histopathology, and other test indicators.

 

Carcinogenicity Test (Project Duration: ~32–34 months)

The purpose of the carcinogenicity test is to assess tumor development in test animals during or after exposure to different doses of the test material through appropriate routes, covering major life stages of the animals.

 

- If an extract-based test is used, a standalone carcinogenicity study can be conducted according to OECD TG 451, or a combined chronic toxicity and carcinogenicity study can be conducted following OECD TG 453 to comprehensively evaluate both biological endpoints while considering the possibility of solid-state carcinogenicity.

- When evaluating the carcinogenicity of a medical device using a single animal species, the selection and justification should follow ISO 10993-2.

- For rodents, each group should include at least 50 animals per sex, with the study typically lasting 24 months to cover most of the animal’s lifespan.

 

Evaluation criteria include body weight, clinical observations, tumor formation and progression, hematology, gross pathology, histopathology, and other test indicators. Although transgenic animals can be used for carcinogenicity tests, their application in medical device evaluations has not yet been established.

 

Alternatives to Animal Testing for Chronic Toxicity and Carcinogenicity Evaluations

Both chronic toxicity and carcinogenicity studies involve long-term animal testing, posing significant financial and time challenges for product development. So, is animal testing always necessary for evaluating these biological endpoints?

 

According to iso 10993-18 (Material Chemical Characterization) and ISO 10993-17 (Toxicological Risk Assessment), toxicological evaluations based on material characterization can be used for assessing systemic toxicity endpoints, including:

 

- Systemic toxicity (acute, subacute, subchronic, and chronic toxicity)

- Genotoxicity

- Reproductive toxicity

- Carcinogenicity

 

Therefore, when determining whether to conduct chronic toxicity and carcinogenicity studies, it is essential to first consider the intended use and classification of the device to identify whether these biological endpoints require evaluation.

 

Manufacturers should leverage existing product information as much as possible, including raw materials, manufacturing processes, preclinical and clinical data (if available). When additional studies are necessary to support risk assessment, a tiered approach is recommended:

 

1. Prioritize chemical and physical characterization

2. Perform in vitro screening tests

3. Review characterization and in vitro test results before proceeding with animal testing

4. Justify the necessity of long-term animal studies

 

By following this approach, the biological risk assessment can be conducted in a scientifically rational and efficient manner.


Email:hello@jjrlab.com


Leave Your Message


Write your message here and send it to us


Related News
Read More >>
EMC Testing Lab IEC 60601 Medical Electrical Safet EMC Testing Lab IEC 60601 Medical Electrical Safet
10 .03.2026
EMC testing for IEC 60601 medical electrical safety by China JJR Laboratory covers IEC 60601-1, IEC ...
What are the FCC Testing Requirements for Bluetoot What are the FCC Testing Requirements for Bluetoot
10 .02.2026
FCC Bluetooth device certification testing by China JJR Laboratory covers 47 CFR Part 15, ANSI C63.1...
Australia RCM Certification for Radio Devices Australia RCM Certification for Radio Devices
10 .01.2026
Australia RCM certification for radio devices by China JJR Laboratory covers AS/NZS 4268, CISPR 32, ...
RED Cybersecurity EN 18031 Standard RED Cybersecurity EN 18031 Standard
10 .01.2026
RED Cybersecurity EN 18031 testing by China JJR Lab covers EN 18031-1/-2/-3, RED 3.3(d/e/f), CE comp...
Compliance Testing for EMC Compliance Testing for EMC
10 .01.2026
Compliance Testing for EMC by China JJR Laboratory covers CE, FCC, ISED, RCM, MIC and KC standards, ...
What is Amazon Toy Compliance? What is Amazon Toy Compliance?
09 .30.2026
Amazon Toy Compliance Testing by JJR Laboratory covers ASTM F963-23, CPSIA and EN 71 standards, help...
What is Cytotoxicity ISO 10993-5 What is Cytotoxicity ISO 10993-5
09 .29.2026
ISO 10993-5 cytotoxicity testing at JJR LAB uses cell culture hardware and analyzers to measure cell...
What is Hemocompatibility Testing ISO 10993? What is Hemocompatibility Testing ISO 10993?
09 .29.2026
ISO 10993-4 hemocompatibility testing uses blood-contact test systems, flow probes and analyzers to ...

Leave Your Message